ligufalimab (AK117) / Akesobio |
NCT06601335: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) |
|
|
| Recruiting | 3 | 510 | RoW | AK117 in combination with AK112, Placebo in combination with Pembrolizumab | Akeso | Head and Neck Squamous Cell Carcinoma | 01/27 | 10/27 | | |
| Recruiting | 2 | 254 | US, RoW | AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan, Leucovorin, 5-fluorouracil | Akeso, Summit Therapeutics | Metastatic Colorectal Cancer | 05/26 | 08/28 | | |
| Recruiting | 2 | 120 | RoW | AK117, AK112, Nab paclitaxel, paclitaxel | Akeso | Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer | 07/25 | 12/26 | | |
AK117-205, NCT06196203: A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes |
|
|
| Recruiting | 2 | 90 | US, RoW | AK117, Placebo, Azacitidine | Akeso | Higher-risk Myelodysplastic Syndromes | 01/26 | 06/26 | | |
| Not yet recruiting | 2 | 10 | NA | AK117, anti-EGFR | West China Hospital | Head and Neck Squamous Cell Carcinoma | 08/26 | 08/27 | | |
AK104-219, NCT05960955: Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Cadonilimab, AK117, Oxaliplatin, Tegafur-gimeracil-oteracil potassium, Docetaxel, 5-Fluorouracil | Akeso | Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | 11/24 | 11/27 | | |
NCT06789848: Ligufalimab and Cadonilimab in Advanced Liver Cancers |
|
|
| Recruiting | 2 | 64 | US | Ligufalimab, Cadonilimab | University of Texas Southwestern Medical Center, Akesobio, Josephine Hughes Sterling Foundation | Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer | 05/29 | 05/30 | | |
| Active, not recruiting | 1/2 | 250 | RoW | AK112, AK117, Chemotherapy | Akeso | Advanced Malignant Tumors | 05/25 | 06/26 | | |
| Recruiting | 1/2 | 114 | RoW | AK112, AK117, Carboplatin, Cisplatin, 5-Fluorouracil | Akeso | Advanced Malignant Tumors | 02/23 | 02/24 | | |
AK117-204, NCT05235542: A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 130 | RoW | AK104, AK117, Capecitabine tablets, Oxaliplatin, Cisplatin, Paclitaxel, Irinotecan, Docetaxel, 5-FU | Akeso | Advanced Malignant Tumors | 03/23 | 03/24 | | |
| Active, not recruiting | 1/2 | 136 | RoW | AK117, Azacitidine | Akeso | Myelodysplastic Syndrome | 09/25 | 12/25 | | |
| Active, not recruiting | 1/2 | 68 | RoW | AK117, Azacitidine | Akeso | Acute Myeloid Leukemia | 09/25 | 12/25 | | |
AK117-206, NCT06387420: A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 1/2 | 180 | RoW | AK117, Azacitidine, Venetoclax, Placebo | Akeso | ACUTE MYELOID LEUKEMIA; AML | 04/26 | 04/27 | | |
NCT06642792: A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma |
|
|
| Recruiting | 1/2 | 280 | RoW | AK129, AK117 | Akeso | Classic Hodgkin Lymphoma | 11/27 | 02/28 | | |
| Completed | 1 | 49 | RoW | AK117 | Akeso | Neoplasms Malignant | 01/22 | 05/23 | | |